Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Tissue Microarrays for Routine Diagnostic Assessment of HER2 Status in Breast Carcinoma

Tissue Microarrays for Routine Diagnostic Assessment of HER2 Status in Breast Carcinoma TECHNICAL ARTICLE Tissue Microarrays for Routine Diagnostic Assessment of HER2 Status in Breast Carcinoma Primozˇ Drev, DVM, MS, Snjezˇana Frkovic´ Grazio, MD, PhD, and Matej Bracˇko, MD, PhD Breast cancers that overexpress HER2 have unfavorable Abstract: The use of tissue microarray (TMA) technology may prognosis and show several distinctive features: they are substantially reduce the costs of routine testing of breast typically poorly differentiated, have a high proliferative carcinomas for human epidermal growth factor receptor 2 rate, often lack hormone receptors, and tend to present at (HER2) status. After a preliminary pilot study comparing the a more advanced stage. TMA results with those obtained on whole section, which Apart from its prognostic role, HER2 status showed an excellent agreement (with kappa values >0.90) for impacts the treatment of breast cancer as it predicts both immunohistochemical and fluorescent in situ hybridization response to certain anticancer therapies. HER2 positivity (FISH) method, we introduced the TMA technique in our is apparently associated with relative resistance to routine work. A total of 1158 invasive breast carcinomas were endocrine therapies. Furthermore, women with HER2- submitted for the determination of HER2 status, which was positive tumors might be relatively resistant to alkylating assessed in 74 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Applied Immunohistochemistry & Molecular Morphology Wolters Kluwer Health

Tissue Microarrays for Routine Diagnostic Assessment of HER2 Status in Breast Carcinoma

Loading next page...
 
/lp/wolters-kluwer-health/tissue-microarrays-for-routine-diagnostic-assessment-of-her2-status-in-hmyQqKpBU6

References (32)

ISSN
1541-2016
DOI
10.1097/PAI.0b013e31806875e1
pmid
18227723
Publisher site
See Article on Publisher Site

Abstract

TECHNICAL ARTICLE Tissue Microarrays for Routine Diagnostic Assessment of HER2 Status in Breast Carcinoma Primozˇ Drev, DVM, MS, Snjezˇana Frkovic´ Grazio, MD, PhD, and Matej Bracˇko, MD, PhD Breast cancers that overexpress HER2 have unfavorable Abstract: The use of tissue microarray (TMA) technology may prognosis and show several distinctive features: they are substantially reduce the costs of routine testing of breast typically poorly differentiated, have a high proliferative carcinomas for human epidermal growth factor receptor 2 rate, often lack hormone receptors, and tend to present at (HER2) status. After a preliminary pilot study comparing the a more advanced stage. TMA results with those obtained on whole section, which Apart from its prognostic role, HER2 status showed an excellent agreement (with kappa values >0.90) for impacts the treatment of breast cancer as it predicts both immunohistochemical and fluorescent in situ hybridization response to certain anticancer therapies. HER2 positivity (FISH) method, we introduced the TMA technique in our is apparently associated with relative resistance to routine work. A total of 1158 invasive breast carcinomas were endocrine therapies. Furthermore, women with HER2- submitted for the determination of HER2 status, which was positive tumors might be relatively resistant to alkylating assessed in 74

Journal

Applied Immunohistochemistry & Molecular MorphologyWolters Kluwer Health

Published: Mar 1, 2008

There are no references for this article.